Edwards Lifesciences stock before the bell after a 0.0 percent move.
π Edwards Lifesciences closed at $88.22 on September 18, 2026, with a negligible 0.01% decline from the prior session.
π° The company reported EPS of $0.78 and revenue of $1.74 billion for the July quarter, supporting its stock price near $88.
π MarketBeat confirmed Q3 2026 guidance of $0.710 to $0.770 per share as the latest dated outlook for investors.
π― Full fiscal year 2026 EPS guidance stands between $2.950 and $3.050 per share according to recent reports.
π The stock traded with a volume of 4.25 million shares, remaining 8.3% below its 52-week high.
Bullish Signals
- Edwards Lifesciences reported an EPS of $0.78 and revenue of $1.74 billion for the July quarter, indicating solid financial performance.
- The stock remained stable near $88 following the earnings beat, suggesting investor confidence in the company's recent results.
Risk Factors
- The shares closed down 0.01% from the previous session, reflecting a flat or slightly bearish short-term sentiment.
Full Analysis
Edwards Lifesciences (NYSE: EW) closed at $88.22 on September 18, 2026, showing a negligible 0.01% decline from the previous session. The stock traded within a range of $87.96 to $88.65 with a volume of 4.25 million shares, maintaining a market capitalization of approximately $50.80 billion. At this price point, the shares remained 8.3% below their 52-week high but were still trading 21.1% above their 52-week low.
The company's recent performance was supported by its July quarter results, where it reported earnings per share (EPS) of $0.78 on revenue of $1.74 billion. This earnings beat helped stabilize the stock price near the $88 level following the report. MarketBeat noted that these figures provided a solid foundation for investor sentiment heading into the current trading session.
Looking ahead, Edwards Lifesciences has issued guidance for the third quarter of 2026 with EPS expected between $0.710 and $0.770 per share. For the full fiscal year 2026, the company projects EPS to range from $2.950 to $3.050. These forward-looking metrics represent the latest official outlook available for investors as they assess the stock's trajectory before the bell.